Glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease: a narrative review
Quality in Sport · 26.06.2026 · 60 · 72834
DOI: 10.12775/qs.2026.60.72834 ↗Kurz gefasst
Fachartikel in der Zeitschrift Quality in Sport, online erschienen am 26.06.2026. Verfasst von Martyna Małek und 9 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
Background
Metabolic dysfunction-associated steatotic liver disease (MASLD) is one of themost common chronic liver diseases worldwide and is strongly linked to obesity and type 2diabetes mellitus. Glucagon-like peptide-1 (GLP-1) receptor agonists have gained attentionbecause of their hepatoprotective and cardiometabolic effects.
Aim
This narrative review summarizes current evidence on GLP-1 receptor agonists in thetreatment of MASLD and metabolic dysfunction-associated steatohepatitis (MASH).Materials and methods: A literature review was conducted using PubMed, Scopus and GoogleScholar. Included studies comprised clinical trials, randomized controlled trials, meta-analyses,review articles and international guidelines published between 2021 and 2025.
Results
Evidence suggests that GLP-1 receptor agonists, especially semaglutide andliraglutide, reduce hepatic steatosis, insulin resistance, body weight and inflammatory activityin patients with MASLD or MASH. Several studies demonstrated improvements in liverhistology and non-invasive fibrosis markers, although antifibrotic effects were less consistentin advanced cirrhosis. These agents also improved glycemic control and cardiovascular riskfactors, with an acceptable safety profile.
Conclusions
GLP-1 receptor agonists appear to be a promising therapeutic option for MASLDand MASH. However, further long-term randomized studies are required to confirm theireffects on fibrosis and liver-related outcomes.
Zitieren
APA
Małek, M., Denkiewicz, A., Denkiewicz, K., Pachulska, K., Dorosz, W., Podolak, M., Nawracaj, M., Miłkowska, M., Bartczak, J., & Sosiński, P. (2026). Glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease: a narrative review. Quality in Sport, 60, 72834. https://doi.org/10.12775/qs.2026.60.72834
Vancouver
Małek M, Denkiewicz A, Denkiewicz K, Pachulska K, Dorosz W, Podolak M, et al. Glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease: a narrative review. Quality in Sport. 2026;60:72834. doi:10.12775/qs.2026.60.72834
BibTeX
@article{Maek2026,
author = {Małek, Martyna and Denkiewicz, Aleksandra and Denkiewicz, Karolina and Pachulska, Klaudia and Dorosz, Weronika and Podolak, Maja and Nawracaj, Michał and Miłkowska, Maria and Bartczak, Julia and Sosiński, Piotr},
title = {Glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease: a narrative review},
journal = {Quality in Sport},
year = {2026},
volume = {60},
pages = {72834},
doi = {10.12775/qs.2026.60.72834}
}
EUVIMED